VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15
May 06 2019 - 7:00AM
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that it
will host a conference call and live audio webcast on Wednesday,
May 15 at 8:30am Eastern Time to report first quarter ended March
31, 2019 financial results and to provide a corporate update.
Wednesday, May 15th @ 8:30am
Eastern Time |
From the US: |
877-407-9208 |
International: |
201-493-6784 |
Conference ID: |
13690495 |
Webcast: |
https://edge.media-server.com/m6/p/ajc44j7z |
|
|
About VBLVascular Biogenics
Ltd., operating as VBL Therapeutics, is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class treatments for cancer. VBL’s
lead oncology product candidate, ofranergene obadenovec (VB-111),
is a first-in-class, targeted anti-cancer gene-therapy agent that
is being developed to treat a wide range of solid tumors. It is
conveniently administered as an IV infusion once every two months.
It has been observed to be well-tolerated in >300 cancer
patients and demonstrated activity signals in an “all comers” Phase
1 trial as well as in three tumor-specific Phase 2 studies.
Ofranergene obadenovec is currently being studied in a Phase 3
potential registration trial for platinum-resistant ovarian
cancer.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From May 2023 to May 2024